{"id":54756,"date":"2023-03-13T13:05:42","date_gmt":"2023-03-13T12:05:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/"},"modified":"2023-03-13T13:05:42","modified_gmt":"2023-03-13T12:05:42","slug":"anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/","title":{"rendered":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–#ELCC2023<\/a>—AnHeart Therapeutics<\/a> (\u201cAnHeart\u201d), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1.\n<\/p>\n

<\/a><\/p>\n

\nThis oral presentation at ELCC 2023 will provide updated efficacy and safety data of taletrectinib regional Phase 2 study (TRUST-I, NCT04395677) with about 1.5-year follow-up in patients. Taletrectinib is a potent, next-generation, CNS-active, ROS1 tyrosine kinase inhibitor (TKI). In previous reports from the TRUST-I study, taletrectinib showed meaningful clinical efficacy and favorable safety profiles in patients with ROS1+ NSCLC (n=109) regardless of crizotinib pretreatment status.\n<\/p>\n

\nSeparately, a global taletrectinib Phase 2 clinical trial (TRUST-II, NCT04919811) is ongoing and actively enrolling patients in North America, Europe and Asia.\n<\/p>\n

\nThe details of the oral presentation are as follows:\n<\/p>\n

\nTitle:<\/b> Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer (NSCLC)\n<\/p>\n

\nPresentation Session Number:<\/b> 14MO\n<\/p>\n

\nPresenter:<\/b> Dr. Wei Li, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China\n<\/p>\n

\nDate:<\/b> Friday March 31, 2023\n<\/p>\n

\nLocation: <\/b>Auditorium 1, Bella Center Copenhagen, Copenhagen, Denmark\n<\/p>\n

\nThe ELCC 2023 Program can be accessed online at: https:\/\/cslide.ctimeetingtech.com\/elcc23hybrid\/attendee\/confcal\/session\/calendar\/2023-03-31<\/a>.\n<\/p>\n

\nAbout AnHeart Therapeutics<\/b>\n<\/p>\n

\nAnHeart Therapeutics (\u201cAnHeart\u201d) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-na\u00efve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment na\u00efve or previously treated with crizotinib. The Company\u2019s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China. For more information, visit www.anhearttherapeutics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
Weiqing Wang, PhD
\n
212-466-6378
\n
ir@anhearttherapeutics.com<\/a>\n<\/p>\n

\nMedia Contact:
\n
Kimberly Ha
\n
KKH Advisors
\n
917-291-5744
\n
kimberly.ha@kkhadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–#ELCC2023—AnHeart Therapeutics (\u201cAnHeart\u201d), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1. This oral presentation at ELCC 2023 will provide updated efficacy and safety … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54756","6":"format-standard","7":"category-industry"},"yoast_head":"\nAnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–#ELCC2023—AnHeart Therapeutics (\u201cAnHeart\u201d), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1. This oral presentation at ELCC 2023 will provide updated efficacy and safety ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-13T12:05:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023\",\"datePublished\":\"2023-03-13T12:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/\"},\"wordCount\":400,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005024\\\/en\\\/1734374\\\/21\\\/AnHeart_Logo_2_%281%29_%283%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/\",\"name\":\"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005024\\\/en\\\/1734374\\\/21\\\/AnHeart_Logo_2_%281%29_%283%29.jpg\",\"datePublished\":\"2023-03-13T12:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005024\\\/en\\\/1734374\\\/21\\\/AnHeart_Logo_2_%281%29_%283%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005024\\\/en\\\/1734374\\\/21\\\/AnHeart_Logo_2_%281%29_%283%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/","og_locale":"en_US","og_type":"article","og_title":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–#ELCC2023—AnHeart Therapeutics (\u201cAnHeart\u201d), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1. This oral presentation at ELCC 2023 will provide updated efficacy and safety ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-13T12:05:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023","datePublished":"2023-03-13T12:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/"},"wordCount":400,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/","url":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/","name":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg","datePublished":"2023-03-13T12:05:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230313005024\/en\/1734374\/21\/AnHeart_Logo_2_%281%29_%283%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/anheart-therapeutics-announces-oral-presentation-at-the-european-lung-cancer-congress-elcc-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54756"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54756\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}